CEACAM8

Summary

CEACAM8 (CEA cell adhesion molecule 8, HGNC:1820) is a protein-coding gene on chromosome 19q13.2, encoding Cell adhesion molecule CEACAM8 (P31997). Cell surface glycoprotein that plays a role in cell adhesion in a calcium-independent manner.

Enables protein heterodimerization activity. Involved in heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules. Located in cell surface and extracellular space. Biomarker of severe acute respiratory syndrome.

Source: NCBI Gene 1088 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 63 total
• MANE Select transcript: NM_001816

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1820
Approved symbol	CEACAM8
Name	CEA cell adhesion molecule 8
Location	19q13.2
Locus type	gene with protein product
Status	Approved
Aliases	CD66b
Ensembl gene	ENSG00000124469
Ensembl biotype	protein_coding
OMIM	615747
Entrez	1088

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000244336, ENST00000599005, ENST00000899996, ENST00000899997

RefSeq mRNA: 1 — MANE Select: NM_001816 NM_001816

CCDS: CCDS12610

Canonical transcript exons

ENST00000244336 — 6 exons

Exon	Start	End
ENSE00001415045	42583206	42583337
ENSE00001510272	42580243	42581353
ENSE00002430527	42588784	42589038
ENSE00002503260	42589457	42589735
ENSE00002516431	42594765	42594924
ENSE00002530103	42593541	42593900

Expression profiles

Bgee: expression breadth ubiquitous, 116 present calls, max score 99.49.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.5140 / max 278.8940, expressed in 43 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
181202	0.2898	25
181203	0.2210	31
181204	0.0032	1

Top tissues by expression

259 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
trabecular bone tissue	UBERON:0002483	99.49	gold quality
bone marrow	UBERON:0002371	98.47	gold quality
bone marrow cell	CL:0002092	97.66	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.86	gold quality
mononuclear cell	CL:0000842	77.68	gold quality
monocyte	CL:0000576	77.51	gold quality
leukocyte	CL:0000738	76.84	gold quality
blood	UBERON:0000178	75.27	gold quality
granulocyte	CL:0000094	65.44	gold quality
spleen	UBERON:0002106	64.45	gold quality
mucosa of transverse colon	UBERON:0004991	61.18	gold quality
right lung	UBERON:0002167	61.03	gold quality
adrenal tissue	UBERON:0018303	55.06	gold quality
upper lobe of left lung	UBERON:0008952	50.95	gold quality
upper lobe of lung	UBERON:0008948	50.61	gold quality
frontal pole	UBERON:0002795	50.41	gold quality
lung	UBERON:0002048	50.33	gold quality
middle frontal gyrus	UBERON:0002702	50.30	gold quality
sural nerve	UBERON:0015488	50.24	silver quality
paraflocculus	UBERON:0005351	50.18	gold quality
Brodmann (1909) area 10	UBERON:0013541	50.18	gold quality
thymus	UBERON:0002370	49.99	silver quality
quadriceps femoris	UBERON:0001377	49.90	gold quality
vastus lateralis	UBERON:0001379	49.45	gold quality
Brodmann (1909) area 46	UBERON:0006483	49.30	gold quality
blood vessel layer	UBERON:0004797	49.29	gold quality
cerebellar vermis	UBERON:0004720	49.25	gold quality
cervix squamous epithelium	UBERON:0006922	49.20	gold quality
hair follicle	UBERON:0002073	49.18	gold quality
olfactory bulb	UBERON:0002264	48.92	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	3189.16
E-ANND-3	yes	12.17

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

71 targeting CEACAM8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AB	99.95	71.31	3488
HSA-MIR-559	99.95	72.28	3609
HSA-MIR-548A-5P	99.94	71.27	3482
HSA-MIR-548AD-5P	99.94	71.23	3502
HSA-MIR-548AE-5P	99.94	71.23	3502
HSA-MIR-548AK	99.94	71.24	3488
HSA-MIR-548AM-5P	99.94	71.24	3488
HSA-MIR-548AP-5P	99.94	71.14	3489
HSA-MIR-548AQ-5P	99.94	71.34	3426
HSA-MIR-548AR-5P	99.94	71.28	3515
HSA-MIR-548AS-5P	99.94	71.22	3482
HSA-MIR-548AU-5P	99.94	71.24	3488
HSA-MIR-548AY-5P	99.94	71.23	3502
HSA-MIR-548B-5P	99.94	71.23	3502
HSA-MIR-548BB-5P	99.94	71.27	3509
HSA-MIR-548C-5P	99.94	71.24	3488

Literature-anchored findings (GeneRIF, showing 13)

• All the leukemic samples showed overexpression of CEACAM6 and 8 when compared with normal granulocytes. (PMID:17909799)
• CD66b molecules are involved in regulating adhesion and activation of eosinophils, possibly through their localization in lipid rafts and interaction with other cell surface molecules, such as CD11b. (PMID:18056392)
• Data show that desensitization of neutrophils to any two CEACAMs, 1, 3, 6, or 8, results in selective desensitization to those two CEACAMs, while the cells remain responsive to the other two neutrophil CEACAMs. (PMID:19077207)
• The highly elevated gene expression of CEACAM6 and CEACAM8 in primary myelofibrosis can serve as molecular markers of myelofibrotic transformation. (PMID:21470677)
• Granulocytes from type 2 diabetes patients display higher granulocyte cell surface expression of CD66b compared with values of healthy controls. (PMID:23686079)
• CEACAM8 interacts with CEACAM1 inhibiting TLR2-triggered immune responses (PMID:24743304)
• Inhibition of C5aR1 leads to a significant reduction of CD66b and CD11b expression indicating a lower neutrophil activation status and block of granule exocytosis. (PMID:26176669)
• Data suggest ways in which carcinoembryonic antigen-related cell adhesion molecules CEACAM6 and CEACAM8 regulate the biological functions of one another. (PMID:26483485)
• a 7-gene signature was identified which correctly predicted the primary prefibrotic myelofibrosis group with a sensitivity of 100% and a specificity of 89%. The 7 genes included MPO, CEACAM8, CRISP3, MS4A3, CEACAM6, HEMGN, and MMP8 (PMID:27579896)
• Increased CD66b positive tumor-infiltrating neutrophils (CD66b + TINs) was significantly associated with presence of metastasis, S stage, and nonseminomatous germ cell tumor diagnosis. (PMID:27863478)
• High CEACAM8 expression is associated with metastases in breast carcinoma. (PMID:31222613)
• CD66b(+) monocytes represent a proinflammatory myeloid subpopulation in cancer. (PMID:32632664)
• Clinical Significance of CD66b Expression in Non-Small Cell Lung Cancer. (PMID:37162631)

Cross-species orthologs

0 orthologs

Paralogs (24): CEACAM21 (ENSG00000007129), CEACAM7 (ENSG00000007306), CEACAM1 (ENSG00000079385), CEACAM6 (ENSG00000086548), CEACAM4 (ENSG00000105352), CEACAM5 (ENSG00000105388), PSG8 (ENSG00000124467), HEPACAM (ENSG00000165478), PSG6 (ENSG00000170848), CEACAM3 (ENSG00000170956), PSG9 (ENSG00000183668), CEACAM19 (ENSG00000186567), HEPACAM2 (ENSG00000188175), PSG5 (ENSG00000204941), CEACAM18 (ENSG00000213822), CEACAM16 (ENSG00000213892), VSTM5 (ENSG00000214376), PSG3 (ENSG00000221826), PSG7 (ENSG00000221878), PSG1 (ENSG00000231924), PSG2 (ENSG00000242221), PSG11 (ENSG00000243130), PSG4 (ENSG00000243137), CEACAM20 (ENSG00000273777)

Protein

Protein identifiers

Cell adhesion molecule CEACAM8 — P31997 (reviewed: P31997)

Alternative names: CD67 antigen, Carcinoembryonic antigen CGM6, Carcinoembryonic antigen-related cell adhesion molecule 8, Non-specific cross-reacting antigen NCA-95

All UniProt accessions (3): P31997, M0R1X3, Q0Z7S6

UniProt curated annotations — full annotation on UniProt →

Function. Cell surface glycoprotein that plays a role in cell adhesion in a calcium-independent manner. Mediates heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6. Heterophilic interaction with CEACAM8 occurs in activated neutrophils.

Subunit / interactions. Monomer. Heterodimer with CEACAM6; heterodimerizes via its Ig-like V-type domain.

Subcellular location. Cell membrane. Cell surface.

Tissue specificity. Expressed in leukocytes of chronic myeloid Leukemia patients and bone marrow.

Post-translational modifications. Glycosylated.

Domain organisation. The N-terminus Ig-like V-type domain is necessary for heterophilic intercellular adhesion.

Similarity. Belongs to the immunoglobulin superfamily. CEA family.

RefSeq proteins (1): NP_001807* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR007110	Ig-like_dom	Domain
IPR013106	Ig_V-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050831	CEA_cell_adhesion	Family

Pfam: PF07686, PF13895, PF13927

UniProt features (48 total): glycosylation site 11, mutagenesis site 10, strand 9, sequence variant 5, domain 3, disulfide bond 2, helix 2, turn 2, signal peptide 1, chain 1, propeptide 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
4Y88	X-RAY DIFFRACTION	1.45
4YIQ	X-RAY DIFFRACTION	1.85
4WTZ	X-RAY DIFFRACTION	2.52
2DKS	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P31997-F1	87.26	0.79

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 320

Disulfide bonds (2): 167–215, 259–299

Glycosylation sites (11): 152, 173, 197, 224, 256, 274, 288, 309, 104, 111, 115

Mutagenesis-validated functional residues (10):

Position	Phenotype
40–45	no effect on heterophilic cell adhesion.
61–63	no effect on heterophilic cell adhesion.
66	inhibits heterophilic cell adhesion.
72–75	no effect on heterophilic cell adhesion.
78	does not affect the monomeric structure. loss of heterodimerization with ceacam6.
78	inhibits heterophilic cell adhesion.
85–89	no effect on heterophilic cell adhesion.
97	no effect on heterophilic cell adhesion.
123	does not affect the monomeric structure. decreases heterodimerization with ceacam6.
129	does not affect the monomeric structure. loss of heterodimerization with ceacam6.

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-1566977	Fibronectin matrix formation
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-6798695	Neutrophil degranulation
R-HSA-109582	Hemostasis
R-HSA-1474244	Extracellular matrix organization
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System

MSigDB gene sets: 81 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_HETEROPHILIC_CELL_CELL_ADHESION, GOCC_VACUOLAR_MEMBRANE, GOCC_SECRETORY_GRANULE, GOCC_CELL_SURFACE, GOBP_CELL_CELL_ADHESION, SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A4, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_16D_DN, VALK_AML_CLUSTER_15, REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL, GOCC_SECRETORY_VESICLE, GOCC_SPECIFIC_GRANULE, GOCC_SECRETORY_GRANULE_MEMBRANE, GOCC_SIDE_OF_MEMBRANE, GOMF_PROTEIN_HETERODIMERIZATION_ACTIVITY

GO Biological Process (3): immune response (GO:0006955), heterophilic cell-cell adhesion (GO:0007157), cell adhesion (GO:0007155)

GO Molecular Function (2): protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (9): obsolete extracellular space (GO:0005615), plasma membrane (GO:0005886), cell surface (GO:0009986), azurophil granule membrane (GO:0035577), specific granule membrane (GO:0035579), extracellular exosome (GO:0070062), tertiary granule membrane (GO:0070821), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-4 pathways:

Category	Pathways
Extracellular matrix organization	1
Hemostasis	1
Innate Immune System	1
Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
secretory granule membrane	3
membrane	2
immune system process	1
response to stimulus	1
cell-cell adhesion	1
cellular process	1
protein dimerization activity	1
binding	1
cell periphery	1
lysosomal membrane	1
azurophil granule	1
specific granule	1
extracellular vesicle	1
tertiary granule	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

1766 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CEACAM8	CD19	P15391	898
CEACAM8	FCGR3B	O75015	862
CEACAM8	FCGR3A	P08637	860
CEACAM8	ITGAM	P11215	854
CEACAM8	LGALS3	P17931	836
CEACAM8	GYPA	P02724	784
CEACAM8	NCAM1	P13591	782
CEACAM8	FUT4	P22083	773
CEACAM8	LTF	P02788	755
CEACAM8	SELL	P14151	753
CEACAM8	MPO	P05164	748
CEACAM8	ITGB2	P05107	744
CEACAM8	CR1	P17927	736
CEACAM8	CD33	P20138	708
CEACAM8	CD274	Q9NZQ7	679

IntAct

21 interactions, top by confidence:

A	B	Type	Score
CEACAM6	CEACAM8	psi-mi:“MI:0407”(direct interaction)	0.820
CEACAM8	CEACAM6	psi-mi:“MI:0407”(direct interaction)	0.820
CEACAM8	CEACAM6	psi-mi:“MI:0915”(physical association)	0.820
CEACAM8	CEACAM1	psi-mi:“MI:0915”(physical association)	0.710
CEACAM1	CEACAM8	psi-mi:“MI:0915”(physical association)	0.710
CEACAM8	CEACAM1	psi-mi:“MI:0407”(direct interaction)	0.710
CEACAM8	CEACAM8	psi-mi:“MI:0407”(direct interaction)	0.440
ZNF16	CEACAM8	psi-mi:“MI:0915”(physical association)	0.370
ZPLD1	CEACAM8	psi-mi:“MI:0914”(association)	0.350
CEACAM8	PRRT4	psi-mi:“MI:0914”(association)	0.350
ELOA2	XRCC2	psi-mi:“MI:0914”(association)	0.350
RHBDD1	A2ML1	psi-mi:“MI:0914”(association)	0.350
CEACAM8	HS3ST1	psi-mi:“MI:0914”(association)	0.350
CEACAM8	VGF	psi-mi:“MI:0914”(association)	0.350

BioGRID (120): CEACAM8 (Affinity Capture-MS), CEACAM8 (Reconstituted Complex), NMU (Affinity Capture-MS), ITGA8 (Affinity Capture-MS), BMP7 (Affinity Capture-MS), LARGE (Affinity Capture-MS), GPC4 (Affinity Capture-MS), GALNS (Affinity Capture-MS), CPE (Affinity Capture-MS), CHSY3 (Affinity Capture-MS), PTPRS (Affinity Capture-MS), TXNDC11 (Affinity Capture-MS), MGAT5 (Affinity Capture-MS), MANEAL (Affinity Capture-MS), CACNA2D1 (Affinity Capture-MS)

ESM2 similar proteins: A0A0K2S4Q6, A6NI73, O75019, O75022, O75023, O76036, P0C191, P11464, P11465, P13688, P31997, P40199, P59901, Q00887, Q00888, Q00889, Q08708, Q0V881, Q15238, Q16557, Q28110, Q496F6, Q5M7U7, Q5SQ64, Q6GTX8, Q6ISS4, Q6MG56, Q6PI73, Q863H2, Q863H3, Q8C567, Q8IYS5, Q8MHY9, Q8MJZ2, Q8N149, Q8N423, Q8N6C8, Q8VBT3, Q95JB9, Q96LA5

Diamond homologs: A0A0B4J1L0, D3ZQE1, E9QA28, O75871, P06731, P11464, P11465, P13688, P16573, P31809, P31997, P40198, P40199, Q00887, Q00888, Q00889, Q13046, Q14002, Q15238, Q16557, Q2WEN9, Q3KPI0, Q3UKK2, Q61400, Q63111, Q810J1, Q925P2, Q9D2Z1, Q9UQ72, Q9UQ74, A0A140LHF2, P0DP72, P35329, Q15223, Q15746, Q58EX2, Q6V4S5, Q96FE5, Q9D1T0, Q9GL76

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	56
Likely benign	5
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1025 predictions. Top by Δscore:

Variant	Effect	Δscore
19:42591289:T:TA	donor_gain	1.0000
19:42581350:CTGT:C	acceptor_gain	0.9900
19:42589455:A:AC	donor_gain	0.9900
19:42589456:C:CC	donor_gain	0.9900
19:42589731:CTCCG:C	acceptor_gain	0.9900
19:42589732:TCCG:T	acceptor_gain	0.9900
19:42589733:CCG:C	acceptor_gain	0.9900
19:42589733:CCGC:C	acceptor_gain	0.9900
19:42589734:CG:C	acceptor_gain	0.9900
19:42589734:CGC:C	acceptor_gain	0.9900
19:42589736:C:CC	acceptor_gain	0.9900
19:42589738:G:C	acceptor_gain	0.9900
19:42581354:C:CC	acceptor_gain	0.9800
19:42589735:GC:G	acceptor_loss	0.9800
19:42589736:C:CA	acceptor_loss	0.9800
19:42589741:C:CT	acceptor_gain	0.9800
19:42593539:A:AC	donor_gain	0.9800
19:42593540:C:CC	donor_gain	0.9800
19:42589738:G:GC	acceptor_gain	0.9700
19:42589742:A:T	acceptor_gain	0.9700
19:42594759:CCTCA:C	donor_loss	0.9700
19:42594760:CTCAC:C	donor_loss	0.9700
19:42594761:TCA:T	donor_loss	0.9700
19:42594762:CAC:C	donor_loss	0.9700
19:42594764:C:CT	donor_loss	0.9700
19:42589448:GATAC:G	donor_loss	0.9600
19:42589449:ATAC:A	donor_loss	0.9600
19:42589450:TACTC:T	donor_loss	0.9600
19:42589451:ACTC:A	donor_loss	0.9600
19:42589452:C:A	donor_loss	0.9600

AlphaMissense

2260 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:42593764:C:A	W67C	0.983
19:42593764:C:G	W67C	0.983
19:42593766:A:G	W67R	0.982
19:42593766:A:T	W67R	0.982
19:42593645:A:G	L107P	0.964
19:42589626:C:A	W178C	0.962
19:42589626:C:G	W178C	0.962
19:42589516:C:G	C215S	0.961
19:42589517:A:T	C215S	0.961
19:42593607:A:C	Y120D	0.959
19:42589628:A:G	W178R	0.955
19:42589628:A:T	W178R	0.955
19:42593649:A:G	S106P	0.955
19:42593600:A:G	L122P	0.949
19:42588929:C:A	W271C	0.945
19:42588929:C:G	W271C	0.945
19:42589660:C:G	C167S	0.942
19:42589661:A:T	C167S	0.942
19:42589517:A:G	C215R	0.936
19:42593765:C:G	W67S	0.936
19:42593691:C:G	G92R	0.934
19:42593691:C:T	G92R	0.934
19:42588931:A:G	W271R	0.931
19:42588931:A:T	W271R	0.931
19:42593672:C:G	R98P	0.930
19:42589661:A:G	C167R	0.929
19:42589482:A:C	S226R	0.928
19:42589482:A:T	S226R	0.928
19:42589484:T:G	S226R	0.928
19:42589660:C:T	C167Y	0.921

dbSNP variants (sampled 300 via entrez): RS1000088569 (19:42596393 C>A,G,T), RS1000347199 (19:42582077 T>C), RS1000940941 (19:42583523 A>G), RS1000968172 (19:42588029 T>C,G), RS1000972396 (19:42596921 G>T), RS1001085189 (19:42594803 C>A), RS1001149837 (19:42589942 C>T), RS1001273133 (19:42587740 C>T), RS1001482903 (19:42590178 T>G), RS1001632534 (19:42591203 A>C), RS1002021458 (19:42583780 A>C), RS1002315153 (19:42591081 T>A), RS1002530472 (19:42580061 A>G), RS1002792456 (19:42587575 T>C), RS1003164784 (19:42587075 A>C,G)

Disease associations

OMIM: gene MIM:615747 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
fluorene-9-bisphenol	decreases expression	1
titanium dioxide	increases expression	1
ceric oxide	increases expression	1
tamibarotene	affects cotreatment, increases expression	1
perfluorooctane sulfonic acid	increases expression	1
reparixin	decreases reaction, increases expression	1
Allergens	decreases expression	1
Benzo(a)pyrene	increases methylation	1
Tretinoin	increases expression	1
Valproic Acid	decreases methylation	1
Vanadium	increases expression	1
Zinc Oxide	increases expression	1
Coal Ash	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_C0EL	HEK293-CEACAM8-Fc	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.